ALPHA-INTERFERON RAISES SERUM BETA-2-MICROGLOBULIN IN PATIENTS TREATED FOR THROMBOCYTHEMIA

被引：3

作者：

REMES, K ^{[1
]}

TIENHAARA, A ^{[1
]}

PELLINIEMI, TT ^{[1
]}

机构：

[1] UNIV TURKU,CENT HOSP,DEPT CLIN CHEM & HAEMATOL,SF-20520 TURKU 52,FINLAND

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 1993年 / 84卷 / 02期

关键词：

D O I：

10.1111/j.1365-2141.1993.tb03082.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Serum beta-2-microglobulin (b2m) levels were studied in 10 patients treated with alpha interferon (IFN) for thrombocythaemia associated with chronic myeloproliferative diseases. In eight patients the IFN treatment decreased the blood platelet level to < 600 x 10(9)/l. Serum b2m levels rose significantly and dose-dependently immediately after the onset of treatment, by a median maximal increase of 72% with IFN 3 MU every other day, and 95% with 3 MU daily. The b2m rise caused by IFN abolishes the value of serum b2m in states where b2m is used as an indicator of disease activity.

引用

页码：353 / 355

页数：3

共 10 条

[1] BETA-2-MICROGLOBULIN REVIEW - ITS RELEVANCE IN CLINICAL ONCOLOGY [J].

COOPER, EH ;

PLESNER, T .

MEDICAL AND PEDIATRIC ONCOLOGY, 1980, 8 (04) :323-334

[2] IMMUNOLOGICAL IDENTITY OF SMALL SUBUNIT OF HL-A ANTIGENS AND BETA(2)-MICROGLOBULIN AND ITS TURNOVER ON CELL-MEMBRANE [J].

CRESSWEL.P ;

SPRINGER, T ;

STROMING.JL ;

TURNER, MJ ;

GREY, HM ;

KUBO, RT .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1974, 71 (05) :2123-2127

[3] THE PROGNOSTIC VALUE OF SERUM BETA-2 MICROGLOBULIN COMPARED WITH OTHER PRESENTATION FEATURES IN MYELOMATOSIS - (A REPORT TO THE MEDICAL-RESEARCH-COUNCILS WORKING PARTY ON LEUKEMIA IN ADULTS) [J].

CUZICK, J ;

COOPER, EH ;

MACLENNAN, ICM .

BRITISH JOURNAL OF CANCER, 1985, 52 (01) :1-6

[4]

DURIE BGM, 1990, BLOOD, V75, P823

[5] RECOMBINANT ALPHA-2A INTERFERON - AN EFFECTIVE MAINTENANCE AGENT IN ESSENTIAL THROMBOCYTHEMIA [J].

GILES, FJ ;

ANDERSON, CC ;

GRANT, IR ;

HOFFBRAND, AV ;

MEHTA, AB ;

MACHIN, SJ ;

GOLDSTONE, AH .

LEUKEMIA & LYMPHOMA, 1990, 3 (02) :103-107

[6] LONG-TERM INTERFERON THERAPY FOR THROMBOCYTOSIS IN MYELOPROLIFERATIVE DISEASES [J].

GISSLINGER, H ;

LUDWIG, H ;

LINKESCH, W ;

CHOTT, A ;

FRITZ, E ;

RADASZKIEWICZ, T .

LANCET, 1989, 1 (8639) :634-637

[7]

LEHMANN EL, 1975, NONPARAMETRICS

[8] CYTOKINES IN THE CONTROL OF BETA-2 MICROGLOBULIN RELEASE .2. INVIVO STUDIES WITH RECOMBINANT INTERFERONS AND ANTIGENS [J].

NACHBAUR, K ;

TROPPMAIR, J ;

KOTLAN, B ;

KONIG, P ;

AULITZKY, W ;

BIELING, P ;

HUBER, C .

IMMUNOBIOLOGY, 1988, 177 (01) :66-75

[9] TREATMENT OF THROMBOCYTOSIS IN CHRONIC MYELOPROLIFERATIVE DISORDERS WITH INTERFERON ALFA-2B [J].

SEEWANN, HL ;

ZIKULNIG, R ;

GALLHOFER, G ;

SCHMID, C .

EUROPEAN JOURNAL OF CANCER, 1991, 27 :S58-S63

[10] ALPHA INTERFERON RAISES SERUM BETA-2-MICROGLOBULIN IN PATIENTS WITH MULTIPLE-MYELOMA [J].

TIENHAARA, A ;

REMES, K ;

PELLINIEMI, TT .

BRITISH JOURNAL OF HAEMATOLOGY, 1991, 77 (03) :335-338

← 1 →